You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 14, 2024

Investigational Drug Information for Velusetrag


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Velusetrag?

Velusetrag is an investigational drug.

There have been 4 clinical trials for Velusetrag. The most recent clinical trial was a Phase 2 trial, which was initiated on December 15th 2021.

The most common disease conditions in clinical trials are Gastroparesis, Alzheimer Disease, and Intestinal Pseudo-Obstruction. The leading clinical trial sponsors are Theravance Biopharma, Theravance Biopharma R & D, Inc., and Alfasigma S.p.A.

There are six US patents protecting this investigational drug and one hundred and seventy-seven international patents.

Recent Clinical Trials for Velusetrag
TitleSponsorPhase
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).Alfasigma S.p.A.Phase 2
The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) StudyAlfa Wassermann S.p.A.Phase 2
The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) StudyAlfasigma S.p.A.Phase 2

See all Velusetrag clinical trials

Clinical Trial Summary for Velusetrag

Top disease conditions for Velusetrag
Top clinical trial sponsors for Velusetrag

See all Velusetrag clinical trials

US Patents for Velusetrag

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Velusetrag ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Velusetrag ⤷  Sign Up Organic compounds Novartis AG (Basel, CH) ⤷  Sign Up
Velusetrag ⤷  Sign Up Pyrazolo[5,1b]oxazole derivatives as CRF-.sub.1 receptor antagonists Novartis AG (Basel, CH) ⤷  Sign Up
Velusetrag ⤷  Sign Up Organic compounds Novartis AG (Basel, CH) ⤷  Sign Up
Velusetrag ⤷  Sign Up Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists Novartis AG (Basel, CH) ⤷  Sign Up
Velusetrag ⤷  Sign Up Cyclohexyl amide derivatives as CRF receptor antagonists Novartis AG (Basel, CH) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Velusetrag

Drugname Country Document Number Estimated Expiration Related US Patent
Velusetrag Australia AU2017261372 2036-05-05 ⤷  Sign Up
Velusetrag Canada CA3023278 2036-05-05 ⤷  Sign Up
Velusetrag China CN107847398 2036-05-05 ⤷  Sign Up
Velusetrag European Patent Office EP3452003 2036-05-05 ⤷  Sign Up
Velusetrag European Patent Office EP3981392 2036-05-05 ⤷  Sign Up
Velusetrag Hong Kong HK1249728 2036-05-05 ⤷  Sign Up
Velusetrag Japan JP2019520866 2036-05-05 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.